In the neoadjuvant setting, NEOTIDE (NCT05244213) is an ongoing phase 2 trial of sintilimab + chemotherapy in patients with activating EGFR mutations, and NEODANA (NCT04512430) is investigating the use of carboplatin, pemetrexed, bevacizumab, and atezolizumab in the neoadjuvant setting in EGFRm NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.